ALLEGRA MEDICAL TECHNOLOGIES LIMITED (ASX.AMT)

delisted following compulsory acquisition under Listing Rule 17.14

we understand Allegra Innovations Pty Ltd was successful with an offer of A$0.004 cash per Allegra Medical Technologies share

Allegra Innovations Pty Ltd has extended the offer period under its takeover bid for all of the fully paid ordinary shares in Allegra Medical Technologies Limited ACN 066 281 132. The Offer is now scheduled to close at 7.00pm (Sydney time) on Monday, 14 October 2024. A formal notice of variation required by the Corporations Act 2001 (Cth) is released.

Allegra Innovations Pty Ltd has extended the offer period under its takeover bid for all of the fully paid ordinary shares in Allegra Medical Technologies Limited. The Offer is now scheduled to close at 7.00pm (Sydney time) on Monday, 30 September 2024.

The company releases a notification of cessation of securities.

The company has issued a shareholder update. The company has extended its offer period for fully paid ordinary shares, set to close on 16 September 2024. Accepted shares will be paid A$0.004 within 10 business days. Further details can be found in AI's Bidder's Statement from 19 June 2024.

The company has extended its offer period for all fully paid ordinary shares in the company, with the offer set to close on 16 September 2024. A formal notice of variation is attached, and if accepted, participants will receive A$0.004 for each share within 10 business days. Further details can be found in AI's Bidder's Statement from 19 June 2024. If you have already accepted, no action is needed.

The company has issued a shareholder update. The company suspended trading of its shares until it lodges its 2024 annual financial report, as it struggles to do so due to the company's takeover process and strategic and financing options. The company strongly recommends all shareholders accept the takeover offer.

Allegra Innovations Pty Ltd has released a notice of variation of offer. The company extended the offer period under its takeover bid for all of the fully paid ordinary shares in Allegra Medical Technologies Limited ACN 066 281 132. The Offer is now scheduled to close at 7.00pm (Sydney time) on Monday, 2 September 2024.

AI's offer is now unconditional. All AMT shareholders who have already accepted AI's offer will be paid within 10 days from August 8. Shareholders who accept after this date will be paid within 10 days upon receipt of the offer. The offer is set to expire on August 19th 2024, and AI have outlined their intentions for AMT post this date which includes seeking to have AMT shares removed from the official list of ASX. All remaining shareholders who have not yet accepted are encouraged to do so before they expiry date as they may not be able to sell their holdings on-market once the offer period expires.

The company releases a notice of status of conditions.

The company releases a supplementary bidder's statement.

Allegra Innovations declares off-market bid free from conditions.

On July 24, 2024, AI announced it was extending scheduled close from August 8 to Monday August 19, 2024. This extension will provide the opportunity for those shareholders who have not accepted the Offer to do so. Acceptance of the offer remains subject to the conditions of the offer. AMT has released its formal response to the takeover on July 4, 2024 further updated by the release of the Supplementary Target's Statement on July, 19, 2024. The directors continue to unanimously recommend shareholders accept the Offer in the absence of a superior offer and encourage shareholders to read these statements to assist in making an informed decision with respect to the Offer. There are no other operational or financial updates other than what is included in these statements.

Allegra Innovations Pty Ltd (AI) has extended the offer period under its takeover bid for all of the fully paid ordinary shares in Allegra Medical Technologies Limited ACN 066 281 132. The Offer is now scheduled to close at 7.00pm (Sydney time) on Monday, 19 August 2024.

The company releases a First Supplementary Target's Statement.

The securities of the company have been suspended for more than three months. If an entity does not meet the 1 or 2 year deadlines, it will be removed from the official list. The removal will usually take effect from the open of trading on the first trading day after the deadline date.

The Offer of AI is now scheduled to close at 7.00pm (Sydney time) on Monday, 5 August 2024.

In respect of the offers dated 20 June 2024 made by AI under its off-market takeover bid to acquire all of the ordinary shares in AMT, the condition in paragraph 4 of Appendix 2 to the bidder's statement has been fulfilled so that the offers have become free of that condition.

The Company lodges a target's statement in response to the off-market takeover bid by Allegra Innovations Pty Ltd to acquire all ordinary shares in Allegra.

The company releases a supplementary bidder's statement.

Allegra Innovations Pty Ltd is submitting a First Supplementary Bidder's Statement for its off-market takeover bid of Allegra Medical Technologies Limited, as per the Corporations Act 2001, aiming to acquire all ordinary shares.

Allegra Innovations Pty Ltd has submitted an off-market bid to acquire all ordinary shares in Allegra Medical Technologies Limited, as per the Corporations Act 2001, and the offers have been sent to all shareholders.

Allegra Innovations Pty Ltd lodged its Bidder's Statement in respect of the Offer with the Australian Securities and Investments Commission. The Bidder's Statement was also served on Allegra Medical Technologies Limited (ACN 066 281 132) today.

In relation to the proposed acquisition of all the fully paid ordinary shares of Allegra Medical Technologies by AI by way of an off-market takeover bid, AI has set 7:00pm (Sydney time) on Monday the 17th of June 2024 as the time and date for determining those persons to whom information is to be sent under items 6 and 12 of subsection 633(1) of the Corporations Act.

AI and the Board of AMT (other than Mr Nick Hartnell) are pleased to announce that they have entered into an agreement, under which AI proposes to acquire all of the issued shares in AMT by way of a recommended off-market takeover bid. The Board of AMT (other than Mr Nick Hartnell) has unanimously recommended that AMT shareholders accept a cash takeover bid from AI, in the absence of a superior offer and subject to an independent expert concluding that the offer is either fair and reasonable or not fair but reasonable. The Offer comprises of $0.004 cash per AMT share.

The securities of Allegra Medical Technologies Limited were suspended at AMT's request on 23 February 2024 pending the release of an announcement regarding its funding arrangements and sale process relating to the Sr-HT-Gahnite Spinal Cage Device critical to its continued financial viability. AMT's securities will continue to remain suspended until such time that ASX is satisfied with AMT's compliance with the Listing Rules, including Listing Rule 12.2 and that it is otherwise appropriate for AMT's securities to be reinstated to quotation.

The Company further confirms that Appendix 4D and Half Year Report, has been finalised and announced to the market on 22nd March 2024. The ongoing support of the financiers continues to be discussed, negotiated, and assuming satisfactory terms can be agreed, documented. This is envisaged to take up to an additional 2 weeks. Should these discussions complete earlier, the Company will advise the market. The funding arrangements provide the ability for the Company to proceed with the sale of the intellectual property relating to the Sr-HT-Gahnite Spinal Cage Device.

The company lodges its Appendix 4D and Half Year Financial Report.

Allegra has been suspended pursuant to ASX Listing Rule 17.5, effective 1 March 2024, as a result in the delay in lodgment of the Appendix 4D and Half Year Report, which was due to the ASX on 29th February 2024. The delay in the lodgment of the Appendix 4D and Half Year Report has arisen due to the Company's continued discussions with its lenders in relation it's funding requirements, which remain ongoing. It is anticipated that the Half Year Report audit review will be finalized following the successful completion of its funding arrangements with the Company's current financiers. The funding arrangements provide the ability for the Company to proceed with the sale of the intellectual property relating to the Sr-HT-Gahnite Spinal Cage Device. The ongoing support of the financiers continues to be discussed, negotiated, and assuming satisfactory terms can be agreed, documented. This is envisaged to take up to an additional 2 weeks. Should these discussions complete earlier, the Company will advise the market, arrange for the lodgment of the Appendix 4D and Half Year Report, and seek lifting of the suspension at that time.

The securities of Allegra Medical Technologies Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of AMT, pending the release of an announcement regarding its funding arrangements and sale process relating to the Sr-HT-Gahnite Spinal Cage Device critical to its continued financial viability

name changed from Allegra Orthopaedics Limited